Program
cyclobenzaprine
Also written as “TNX-102 SL”, “TNX-102 SL 5.6 mg” and “Treatment A”.
Its studies are mostly in Fibromyalgia · Stress Disorders, Post-Traumatic · Depressive Disorder, Major · Post-Acute COVID-19 Syndrome · Neck Pain, led by 7 companies.
Drug pageCyclobenzaprine: every studyMany companies study it; this page follows only the 32 they lead. All 42 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tonix Pharmaceuticalsits history only | 262 open or running | phase 3since Jul 12, 2013 | Dec 7, 2011 | Feb 2028phase 2 · NCT07621237 |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Apr 24, 2012 | Apr 24, 2012 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Neurana Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 14, 2017 | Nov 14, 2017 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Jun 2, 2009 | Jun 2, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| Takedaits history only | 10 open or running | phase 3since Jun 23, 2016 | Jun 23, 2016 | none ahead |
Also a collaborator on its studies: Altasciences, Premier Research Group and Cognitive Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Oct 28, 2005.
- Apr 25, 2017Phase 1 study in Healthy AdultsTonix Pharmaceuticals · NCT03168022 · 43 enrolled · Canada
- Nov 14, 2017Neurana Pharmaceuticals’ first study: phase 1 study in Driving ImpairedNew to Neurana PharmaceuticalsNeurana Pharmaceuticals · NCT03353922 · 35 enrolled · United States
- Feb 6, 2018Phase 1 study in Healthy SubjectsTonix Pharmaceuticals · NCT03443960 · 60 enrolled · Canada
- Apr 12, 2018Phase 3 study in Stress Disorders, Post-TraumaticTonix Pharmaceuticals · NCT03508700 · 93 enrolled · United States
- Feb 12, 2019Phase 3 study in Stress Disorders, Post-TraumaticTonix Pharmaceuticals · NCT03841773 · 192 enrolled · United States
- Nov 13, 2019Phase 1 study in Healthy SubjectsTonix Pharmaceuticals · NCT04164719 · 16 enrolled · Canada
- Nov 20, 2019Phase 3 study in FibromyalgiaTonix Pharmaceuticals · NCT04172831 · 503 enrolled · United States
- Aug 7, 2020Phase 3 study in FibromyalgiaTonix Pharmaceuticals · NCT04508621 · 514 enrolled · United States
- Mar 1, 2022Phase 3 study in FibromyalgiaTonix Pharmaceuticals · NCT05273749 · 457 enrolled · United States
- May 9, 2022Phase 2 study in Stress Disorders, Post-TraumaticTonix Pharmaceuticals · NCT05372887 · Kenya
- Jul 21, 2022Phase 2 study in InfectionsTonix Pharmaceuticals · NCT05472090 · 63 enrolled · United States
- Jan 26, 2026Phase 1 study in PharmakokineticTonix Pharmaceuticals · NCT07413367 · 50 enrolled · Canada
- Mar 6, 2026Phase 1 study in Healthy Subjects (HS)Tonix Pharmaceuticals · NCT07464535 · 20 enrolled · United States
- May 27, 2026Phase 2 study in Depressive Disorder, MajorTonix Pharmaceuticals · NCT07621237 · 360 planned · United States
Ahead
- Feb 2028Primary completion: phase 2 study in Depressive Disorder, MajorTonix Pharmaceuticals · NCT07621237
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| Trazodonerule | Angelini Pharma | phase 3 | 14 |
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07621237Depressive Disorder, Major · United States | 2 | Recruiting | Tonix Pharmaceuticals | Feb 2028 | 360 |
| NCT07464535Healthy Subjects (HS) · United States | 1 | Completed | Tonix Pharmaceuticals | Apr 30, 2022 | 20 |
| NCT07413367Pharmakokinetic · Canada | 1 | Active, not recruiting | Tonix Pharmaceuticals | Feb 10, 2026 | 50 |
| NCT05472090Infections · United States | 2 | Completed | Tonix Pharmaceuticals | Jul 12, 2023 | 63 |
| NCT05372887Stress Disorders, Post-Traumatic · Kenya | 2 | Withdrawn | Tonix Pharmaceuticals | Nov 8, 2022 | 0 |
| NCT05273749Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Nov 14, 2023 | 457 |
| NCT04508621Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Nov 1, 2021 | 514 |
| NCT04172831Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Oct 29, 2020 | 503 |
| NCT04164719Healthy Subjects · Canada | 1 | Completed | Tonix Pharmaceuticals | Dec 24, 2019 | 16 |
| NCT03841773Stress Disorders, Post-Traumatic · United States | 3 | Terminated | Tonix Pharmaceuticals | Apr 24, 2020 | 192 |
| NCT03508700Stress Disorders, Post-Traumatic · United States | 3 | Completed | Tonix Pharmaceuticals | Sep 30, 2019 | 93 |
| NCT03443960Healthy Subjects · Canada | 1 | Completed | Tonix Pharmaceuticals | Apr 9, 2018 | 60 |
| NCT03353922Driving Impaired · United States | 1 | Completed | Neurana Pharmaceuticals | Dec 6, 2017 | 35 |
| NCT03168022Healthy Adults · Canada | 1 | Completed | Tonix Pharmaceuticals | Jan 26, 2016 | 43 |
| NCT03110575Stress Disorders, Post-Traumatic · United States | 3 | Terminated | Tonix Pharmaceuticals | Jul 27, 2018 | 190 |
| NCT03062540Stress Disorders, Post-Traumatic · United States | 3 | Terminated | Tonix Pharmaceuticals | Jul 27, 2018 | 358 |
| NCT02829814Fibromyalgia · United States | 3 | Terminated | Tonix Pharmaceuticals | Sep 13, 2016 | 51 |
| NCT02814565Neck Pain · Russian Federation | 3 | Completed | Takeda | Feb 10, 2017 | 180 |
| NCT02589275Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Sep 28, 2016 | 375 |
| NCT02436096Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Sep 2016 | 519 |
| NCT02421679Stress Disorders, Post-Traumatic · United States | 2 | Completed | Tonix Pharmaceuticals | May 26, 2016 | 159 |
| NCT02277704Stress Disorders, Post-Traumatic · United States | 2 | Completed | Tonix Pharmaceuticals | May 2016 | 245 |
| NCT02015234Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Aug 2015 | 158 |
| NCT01903265Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Jul 2014 | 205 |
| NCT01889173Healthy Adults · Canada | 1 | Completed | Tonix Pharmaceuticals | Dec 2013 | 24 |
| NCT01689259Healthy Adults · Canada | 1 | Completed | Tonix Pharmaceuticals | Dec 2013 | 24 |
| NCT01634412Healthy Adults · Canada | 1 | Completed | Tonix Pharmaceuticals | Sep 2013 | 24 |
| NCT01587508Acute Lumbago · Brazil | 3 | Withdrawn | Eurofarma Laboratorios | May 2013 | 0 |
| NCT01490788Healthy · Canada | 1 | Completed | Tonix Pharmaceuticals | Dec 30, 2011 | 30 |
| NCT00913419Depression | 1 | Completed | Novartis | Dec 1988 | 30 |
| NCT00778037Healthy · India | – | Completed | Sun Pharmaceutical Industries | Sep 2006 | 40 |
| NCT00246389Pain | 4 | Completed | Johnson & Johnson | 1,000 |
How it is read
Names in the registry
- “TNX-102 SL”, 13 entries
- “TNX-102 SL 5.6 mg”, 2 entries
- “Treatment A”, 2 entries
- “Treatment B”, 2 entries
- “TNX-102 SL Tablet”, 1 entry
Codes read as this program: TNX102.
Conditions, from the studies’ own filings
- Fibromyalgia, 8 studies
- Stress Disorders, Post-Traumatic, 7 studies
- Depressive Disorder, Major, 1 study
- Post-Acute COVID-19 Syndrome, 1 study
- Neck Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.